Lilly’s New Combination Beats its Own Monotherapy
Median PFS doubled to 11.1 months against Inluriyo alone. The comparison payers will run is not in the package.
United States
GENEROUS Signings Jump From Seven to 40 States in a Week
Forty states signed. Reporting last week put it at seven. The list CMS has never published is the manufacturers.
Roche Paid $36.5 Million to Screen 300,000 Bispecific Combinations
Roche has not bought a molecule or a target. It has bought a search, and the pairing is an output rather than an input.
ICER Priced Tavapadon Before the FDA Approved It or AbbVie Named a Price
An assessment body has priced a drug that has neither an approval nor a price. The number will sit in every payer negotiation that follows.
CMS Added Five Tracks to ACCESS. The Payer Pledge Covers 165 Million People Who Cannot Join It.
The expansion is the announcement. Payers covering 165 million pledged to align with a model none of their members can join.
Years After NCCN Recommended It, FET-PET Finally Has an FDA-Approved Drug
The clinical case was settled before the regulatory one. Clinicians held an NCCN recommendation with no lawful product to act on it.
Evernorth Adopts LOCUS in Three States, and States That the Review Process Is Not Changing
Three statutes across five years, discharged on one date. Evernorth says only the source of criteria changes, not the review process itself.
A Jury Convicted the Philips Engineer. The Approach Came as His Plant Was Closing.
The approach came in 2017 as Philips prepared to close the plant. A site closure is a knowledge event before it is a cost event.
DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes
DOJ did not settle with a health plan. It settled with the in-home vendor that supplied the codes, and named the risk-share contract as the incentive.
Avulux Won a De Novo and Created the Category Its Competitors Will File Into
Going first through a De Novo builds the road behind you. Avulux owns the claim today and has created the category rivals will file 510(k)s into.